Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
IL-2 Inhibitor
IL-2-IN-1 is a potent inhibitor of interleukin-2 (IL-2), exhibiting an IC50 value of 1978 nM. It demonstrates significant antiproliferative activity, making it a valuable tool for research in immune modulation and cytokine signaling. This compound is ideal for studies focused on T cell regulation and potential therapeutic applications in autoimmune diseases and cancers linked to IL-2 signaling. -
STING Inhibitor
STING-IN-11 is a potent STING inhibitor with an IC50 of 37.8 nM. By blocking the palmitoylation of the STING protein, it effectively inhibits STING-mediated downstream signaling and associated inflammatory pathways. This compound demonstrates favorable in vivo safety, making it an excellent candidate for research into STING-related inflammatory and autoimmune diseases. -
IL-20/PRINS Inhibitor
Abacavir hydroxyacetate is an orally active inhibitor of IL-20 and PRINS. This compound demonstrates significant immune modulation, effectively reducing the proliferation rate of skin cells in psoriasis. It serves as a valuable tool for investigating inflammatory skin disorders and potential therapeutic strategies in related research applications. -
IL-1β Inhibitor
IL-1β-IN-2 is a potent inhibitor of interleukin-1 beta (IL-1β), a key mediator in inflammatory processes. This cannabigerol derivative exhibits significant anti-inflammatory and analgesic effects, making it a valuable tool for research into conditions driven by IL-1β signaling. IL-1β-IN-2 is suitable for studies focused on inflammatory diseases and pain management, aiding in the understanding and development of therapeutic strategies targeting IL-1β. -
IL-1β Inhibitor
IL-1β-IN-1 is a selective inhibitor of interleukin-1 beta (IL-1β), a key cytokine involved in inflammatory processes. This compound demonstrates significant anti-inflammatory and analgesic effects, making it a valuable tool in research focused on chronic inflammatory conditions and pain management. Its potency and specificity for IL-1β allow for detailed studies on its biological roles and therapeutic applications. -
IL-17 Inhibitor
IL-17-IN-2 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.4 μM, as demonstrated in both HTRF and NHK assays. This compound effectively disrupts IL-17 signaling, making it valuable for research related to inflammatory diseases and immune response modulation. Its significant biological activity allows for exploration in therapeutic contexts targeting IL-17-mediated pathways. -
IL-2 Antibody Inhibitor
Balekafusp alfa is an IgG1K human antibody specifically targeting interleukin-2 (IL-2). It exhibits anti-tumor activity, making it a valuable tool for cancer research and therapeutic studies. This reagent can aid in investigating the immunological mechanisms of IL-2 and its role in tumor progression. Additionally, researchers can utilize it to explore potential applications in immunotherapy and the modulation of immune responses. -
IL-17 Inhibitor
IL-17-IN-5 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.1 μM. This compound is designed for research applications related to inflammatory diseases, facilitating the study of IL-17's role in various pathophysiological processes. IL-17-IN-5 can aid in the development of therapeutic strategies targeting IL-17 signaling pathways. -
IL-1 Inhibitor
Triptoquinone B is a sesquiterpene alkaloid that functions as an interleukin-1 inhibitor. It exhibits significant inhibitory effects on the release of interleukin 1α and 1β from human peripheral mononuclear cells, making it a valuable reagent for studies focused on inflammatory processes and cytokine signaling. This compound is useful for research into immune responses and related therapeutic applications. -
CSF1R/Mer/Axl Inhibitor
Adrixetinib is a potent triple inhibitor targeting CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM respectively. This compound serves as an effective immune modulator by remodeling the tumor microenvironment, enhancing the presence of M1 macrophages and CD8⁺ T cells while reducing M2 macrophages and myeloid-derived suppressor cells (MDSCs). Additionally, Adrixetinib increases the expression of MHC class I and E-cadherin in tumor cells, demonstrating significant antitumor efficacy in syngeneic mouse models. It is relevant for research involving breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma. -
CD44-Hyaluronan Inhibitor
IGFBP-3 peptide is an 18-amino acid fragment of insulin-like growth factor binding protein-3, known to inhibit the interaction between CD44 and hyaluronan. This peptide effectively binds to Humanin and hyaluronan, thereby blocking their functional interactions. IGFBP-3 peptide serves as a useful tool for researching CD44-related signaling pathways and its role in cellular adhesion and migration. -
COX Inhibitor
(±)-Aiphanol is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-1 (IC50 = 1.9 μM) and COX-2 (IC50 = 9.9 μM). This compound displays significant anti-inflammatory properties and further inhibits vascular endothelial growth factor receptor 2 (VEGFR2) with an IC50 of 0.92 μM. By impeding both COX-2 and VEGFR2 pathways, (±)-Aiphanol effectively blocks angiogenesis and induces apoptosis, making it a valuable tool in the study of inflammatory diseases and cancer research. The compound demonstrates oral bioactivity, enhancing its potential for in vivo applications. -
Keap1-Nrf2 Inhibitor
Keap1-Nrf2-IN-11 is a potent inhibitor of the Keap1-Nrf2 interaction, exhibiting a KD2 value of 0.21 nM. This compound effectively reduces the production of reactive oxygen species (ROS) and nitric oxide (NO), as well as downregulating the expression of tumor necrosis factor-alpha (TNF-α). By promoting Nrf2 nuclear translocation, Keap1-Nrf2-IN-11 demonstrates significant anti-inflammatory properties, making it a valuable tool for research in inflammation-related pathways. -
Complement Inhibitor
3-Phenoxybenzaldehyde is a compound identified as a complement inhibitor, exhibiting weak inhibition of the classical pathway of the complement system. This compound demonstrates hemolytic activity, making it relevant for studies related to immune response modulation and complement pathway research. Its applications extend to investigations in autoimmune diseases and therapies targeting complement-mediated cytotoxicity. -
C5 Complement Inhibitor
Avacincaptad pegol is a pegylated RNA aptamer that selectively inhibits complement component C5. By preventing the cleavage of C5 into pro-inflammatory fragments C5a and C5b, this compound mitigates inflammatory cell recruitment and reduces retinal cell damage. Avacincaptad pegol has demonstrated potential in slowing the progression of geographic atrophy (GA) lesions and decreasing the risk of vision loss, making it a valuable tool for research involving age-related macular degeneration (AMD). -
Complement System Inhibitor
Factor B-IN-1 is an inhibitor of Factor B, targeting the complement system to modulate its activity. This compound demonstrates significant inhibition of the alternative pathway of complement activation, making it a valuable tool for studying complement-mediated diseases and immune responses. Factor B-IN-1 is suitable for use in research applications focused on therapeutic interventions and the development of complement-targeted therapies. -
Complement Factor D Inhibitor
Complement Factor D-IN-2 is an inhibitor targeting complement factor D, effectively interrupting the complement cascade at a critical juncture within the alternative complement pathway. By inhibiting factor D, this compound presents valuable opportunities for investigating the role of complement activation in autoimmune diseases. Researchers can utilize Complement Factor D-IN-2 to explore therapeutic strategies aimed at modulating immune responses and mitigating the progression of complement-mediated pathologies. -
Complement Factor D Inhibitor
Refinicopan is a selective inhibitor of complement factor D, demonstrating an IC50 of 10 nM. This compound effectively inhibits rabbit erythrocyte hemolysis with an IC50 of 41 nM, indicating its capacity to modulate complement-mediated processes. Refinicopan's favorable pharmacokinetic and pharmacodynamic properties make it a valuable tool for investigating complement-related disorders and potential therapeutic interventions. -
Complement Protein C5 Inhibitor
Vensobafusp alfa is a fusion protein that targets complement protein C5, functioning as a potent inhibitor. It combines an IgG4 monoclonal antibody directed against C5 with the complement factor H 1-5 domain, demonstrating significant anti-inflammatory and immunomodulatory properties. This reagent is applicable in the study of complement-mediated pathologies and therapeutic strategies targeting inflammatory conditions. -
Complement System Inhibitor
Bisphenol A bissulfate disodium is a complement system inhibitor with a significant role in modulating immune responses. This compound exhibits complement-inhibiting activity, demonstrating an IC50 value of 247 μM. It is utilized in research applications aimed at understanding the complement pathway and its implications in various diseases, making it a valuable tool in immunological studies. -
Complement inhibitor
Bisphenol S disulfate disodium is a complement inhibitor that exhibits a half-maximal inhibitory concentration (IC50) of 660 μM. This compound is utilized in research applications aiming to explore complement-mediated pathways and their roles in various biological processes and diseases. Its ability to modulate complement activity makes it a valuable tool for studies involving immune response and inflammation. -
TLR7/8 Inhibitor
Enpatoran is a potent and orally active dual inhibitor of Toll-like receptors 7 and 8, exhibiting IC50 values of 11.1 nM and 24.1 nM, respectively, in HEK293 cells. This compound is selective, showing no activity against TLR3, TLR4, or TLR9. Enpatoran effectively blocks both synthetic and natural RNA ligands, demonstrating excellent pharmacokinetic properties in vivo. It is a valuable tool for research focused on modulating innate and adaptive immune responses related to autoimmunity. -
TLR3 Inhibitor
CU-CPT 4a is a selective inhibitor of TLR3 signaling, effectively blocking the downstream pathways activated by the TLR3/dsRNA complex. This compound suppresses the production of pro-inflammatory cytokines, including TNF-α and IL-1β, making it a valuable tool for research into immune responses and inflammation. CU-CPT 4a is suitable for studies focused on modulating TLR3-related signaling pathways in various disease models. -
SARM1 Activator/CD38 Inhibitor
Sulfo-ara-F-NMN is a selective SARM1 activator and CD38 inhibitor, functioning as a mimetic of nicotinamide mononucleotide (NMN). It effectively activates SARM1 while inhibiting CD38, with an IC50 of approximately 10 μM. This compound is valuable for research applications focused on the modulation of intracellular cyclic ADP-ribose (cADPR) production and the exploration of pathways involving SARM1 and CD38 in cellular signaling. -
TLR7/TLR9 Inhibitor
AT791 is a potent inhibitor of Toll-like receptors 7 and 9 (TLR7/TLR9), demonstrating strong oral bioavailability. This compound effectively blocks TLR7 and TLR9 signaling pathways in a range of human and murine cell types, as well as inhibiting DNA-TLR9 interactions in vitro. AT791 is applicable in research focused on immune modulation and the characterization of TLR-mediated signaling. -
TLR3/7/9 Inhibitor
ODN 2088 is a potent inhibitor of Toll-like receptors 3, 7, and 9 (TLR3, TLR7, TLR9), demonstrating a strong capacity to modulate immune responses. This compound effectively suppresses the release of key pro-inflammatory cytokines, including interferon-alpha (IFN-α) and interleukin-6 (IL-6), without exhibiting cytotoxic effects. ODN 2088 is valuable for research applications focused on understanding TLR-mediated signaling pathways and their roles in various immune-related conditions. -
Toll-like Receptor (TLR) Inhibitor
Okanin is a potent Toll-like Receptor (TLR) inhibitor derived from the flowering plant Coreopsis tinctoria. It exhibits significant biological activity by attenuating lipopolysaccharide (LPS)-induced microglial activation via the inhibition of the TLR4/NF-κB signaling pathway. This compound is useful for research applications focusing on neuroinflammation and the modulation of immune responses in microglial cells. -
TLR7/8 Inhibitor
Enpatoran hydrochloride is a dual inhibitor of Toll-like receptors 7 and 8, demonstrating potent activity with IC50 values of 11.1 nM and 24.1 nM, respectively, in HEK293 cells. This compound is selectively inactive against TLR3, TLR4, and TLR9, effectively blocking both synthetic and natural RNA ligands. Enpatoran hydrochloride exhibits favorable pharmacokinetic profile in vivo, making it a valuable tool for research into innate and adaptive autoimmunity pathways. -
TLR9 Inhibitor
TLR9-IN-1 is a potent and selective inhibitor of Toll-like receptor 9 (TLR9), exhibiting an IC50 value of 7 nM for human TLR9. This compound is valuable for studying diseases linked to aberrant immune responses, making it an important tool in immunological research and therapeutic development. Researchers can utilize TLR9-IN-1 to explore the modulation of TLR9 pathways in various inflammatory and autoimmune conditions. -
TLR7/TLR8 Inhibitor
TLR7/8-IN-1 is a potent inhibitor of Toll-like receptors 7 and 8, which play critical roles in the immune response. This compound exhibits strong potential in modulating inflammatory pathways associated with autoimmune diseases. It serves as a valuable tool for researchers investigating the therapeutic targeting of TLR7 and TLR8 in various immunological studies. -
TLR4 Inhibitor/PROTAC Linker
TLR4-IN-C34-C2-COOH is a TLR4 inhibitor that serves as a PROTAC linker. It demonstrates significant potential in the modulation of inflammatory responses, particularly in studies involving acute myocardial injury. By targeting TLR4 in enterocytes and macrophages, TLR4-IN-C34-C2-COOH effectively reduces systemic inflammation in murine models of endotoxemia and necrotizing enterocolitis, making it a valuable tool for research in inflammation-related pathways. -
Inflammatory Cell Activation Inhibitor
CI-959 is an inhibitor of inflammatory cell activation, primarily targeting signaling pathways involved in immune response modulation. It demonstrates significant anti-inflammatory and anti-allergic properties by reducing the production of reactive oxygen species in neutrophils, inhibiting neutrophil adhesion, and blocking histamine release from mast cells. CI-959 also effectively suppresses the release of inflammatory mediators, including histamine, leukotrienes, and thromboxane, from guinea pig and human lung tissues. This compound is valuable for research focused on inflammatory and allergic diseases, particularly asthma. -
COX Inhibitor
1-Oxo Ibuprofen is a cyclooxygenase (COX) inhibitor, specifically targeting COX-1 and COX-2 enzymes. As a degradation product and potential impurity of Ibuprofen, it demonstrates significant anti-inflammatory activity with IC50 values of 13 μM for COX-1 and 370 μM for COX-2. This compound is useful for research applications involving the study of prostaglandin synthesis and the metabolic pathways of nonsteroidal anti-inflammatory drugs. -
ERAP1 Inhibitor
ERAP1 modulator-2 is a potent inhibitor of the enzyme ERAP1, exhibiting an IC50 value of less than 100 nM. This compound effectively modulates the activity of ERAP1, influencing peptide trimming and presentation in the context of antigen processing. It is valuable for research applications focused on immune regulation, inflammation, and the modulation of major histocompatibility complex (MHC) class I-mediated responses. -
Anti-inflammatory Agent, Aminopeptidase Inhibitor
2-(2'-Pyridyl)benzimidazole is an effective anti-inflammatory agent and a potent inhibitor of methionine aminopeptidase in Escherichia coli. This compound exhibits tridentate ligand properties, capable of forming stable complexes with various transition metal ions. Its applications extend to biochemical research focused on inflammatory processes and amino acid metabolism, making it a valuable reagent for studies in these areas. -
Keap1/Nrf2 Inhibitor
PRL-295 is an orally active inhibitor targeting the interaction between Keap1 and Nrf2. By enhancing the thermal stability of Keap1, PRL-295 disrupts its binding to Nrf2, leading to the activation of Nrf2-dependent genes such as NAD(P)H:quinone oxidoreductase 1 (NQO1). This compound has demonstrated protective effects against Acetaminophen-induced liver injury in murine models, making it a valuable tool for research into oxidative stress and related pathologies. -
MALT1 Protease Inhibitor
Safimaltib is a potent and selective allosteric inhibitor of MALT1 protease. It exhibits significant biological activity by hindering MALT1's function, which may contribute to tumor stasis in various cancer models. This compound is valuable for research applications exploring the role of MALT1 in oncogenesis and potential therapeutic interventions in malignancies driven by aberrant MALT1 activity. -
MALT1 Inhibitor
MLT-985 is a selective allosteric inhibitor of MALT1, demonstrating an IC50 value of 3 nM. This compound effectively suppresses cell proliferation and intervenes in aberrant signaling associated with the CARD11/BCL10/MALT1 complex. MLT-985 is applicable in research focused on cancer, particularly in the study of B cell malignancies. -
MALT1 Protease Inhibitor
MLT-943 is a selective and orally active inhibitor of MALT1 protease. It effectively inhibits stimulated IL-2 secretion in peripheral blood mononuclear cells (PBMC) and whole blood, demonstrating consistent IC50 values across species (0.07-0.09 μM in PBMC and 0.6-0.8 μM in whole blood). With its notable anti-inflammatory properties, MLT-943 is a valuable reagent for investigating FcγR-mediated inflammatory processes. -
MALT1 Inhibitor
Z-VRPR-FMK is an irreversible inhibitor of the MALT1 protein. It effectively inhibits the growth and invasion of diffuse large B-cell lymphoma by blocking MALT1-induced NF-κB activation and matrix metalloproteinase (MMP) expression. This makes Z-VRPR-FMK a valuable tool for research investigating the role of MALT1 in oncogenesis and therapeutic strategies targeting NF-κB pathways. -
MALT1 Inhibitor
MLT-231 is a potent allosteric inhibitor of MALT1, demonstrating high selectivity with an IC50 of 9 nM. This compound effectively prevents the cleavage of endogenous BCL10, with an IC50 of 160 nM. MLT-231 shows promising antitumor activity in mouse models of activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL), making it a valuable tool for research into therapeutic strategies targeting MALT1-related pathways. -
MALT1 Inhibitor
MALT1-IN-11 is a potent MALT1 protease inhibitor with an IC50 of less than 10 nM. This compound effectively inhibits interleukin-10 (IL-10) secretion, with an IC50 range of 10-100 nM. MALT1-IN-11 is utilized in research focused on cancer, autoimmune diseases, and inflammatory disorders, providing valuable insights into the role of MALT1 in these pathological conditions. -
MALT1 Protease Inhibitor
MALT1-IN-9 is a selective MALT1 protease inhibitor, demonstrating an IC50 of less than 500 nM in Raji MALT1-GloSensor cells. This compound exhibits significant anticancer activity, making it a valuable tool for research focused on targeting MALT1 in various oncological studies. Its efficacy supports investigations into the role of MALT1 in cancer progression and therapeutic development. -
MALT1 Inhibitor
MALT1-IN-5 is a potent inhibitor of the MALT1 protease, targeting the NF-κB signaling pathway. This compound has demonstrated significant biological activity in disrupting MALT1-dependent signaling processes. MALT1-IN-5 is primarily utilized in cancer research to investigate the role of MALT1 in tumorigenesis and its potential as a therapeutic target. -
MALT1 Protease Inhibitor
(R)-MALT1-IN-7 is a selective MALT1 protease inhibitor, designed for investigating the role of MALT1 in various biological processes. It exhibits potent inhibitory activity, making it valuable for cancer research, particularly in studies exploring the underlying mechanisms of tumorigenesis and potential therapeutic interventions. This compound serves as a useful tool in elucidating the function of MALT1 in both normal and pathological cellular contexts. -
MALT1 Inhibitor
MALT1-IN-3 is a selective MALT1 protease inhibitor with a potent IC50 of 0.06 μM. This compound demonstrates inhibitive effects on human IL-6 and IL-10 production in OCI-LY3 cells, exhibiting IC50 values of 0.14 μM and 0.13 μM, respectively. MALT1-IN-3 is valuable for research into gene expression regulation, immune response modulation, and potential therapeutic strategies in various malignancies. -
MALT1 Inhibitor
(R)-MLT-985 is a selective allosteric inhibitor of MALT1, exhibiting an IC50 value of 3 nM. This compound effectively suppresses cell proliferation and disrupts aberrant signaling initiated by the CARD11/BCL10/MALT1 complex. (R)-MLT-985 is primarily utilized in research related to cancer, particularly in the study of B cell malignancies. -
MALT1 Inhibitor
NVS-MALT1 is an allosteric inhibitor of the MALT1 protein, disrupting its activity and providing a valuable tool for studying MALT1-mediated signaling pathways. This compound demonstrates the ability to modulate NF-κB activation and enhance apoptosis in cancer cells, making it relevant for research in oncology and immune response. It is particularly useful in investigations focusing on B-cell lymphoma and other MALT1-associated diseases. -
MALT1 Inhibitor
Ocipumaltib is a potent inhibitor of mucosa-associated lymphoid tissue protein 1 (MALT1), which plays a crucial role in various signaling pathways. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. Additionally, Ocipumaltib is applicable in the study of infection, neurological disorders, and hematological diseases, providing insights into MALT1's involvement in these conditions. -
MALT1 Inhibitor
(S)-MALT1-IN-5 is a potent inhibitor targeting the MALT1 protease. This compound effectively inhibits MALT1 activity, which may provide therapeutic insights for conditions associated with aberrant T cell receptor and B cell receptor signaling, as well as cancers and inflammatory diseases linked to MALT1 dysregulation. (S)-MALT1-IN-5 is a valuable tool for researching MALT1-related disease mechanisms and developing potential interventions.
